首页 > 最新文献

Tuberkuloz ve toraks最新文献

英文 中文
Characteristics of patients with symptomatic and incidental pulmonary thromboembolism. 有症状和偶发肺血栓栓塞症患者的特征。
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403946
Başak Gönen, Pervin Hanci, Osman Nuri Hatipoğlu

Introduction: Pulmonary thromboembolism (PTE) has a wide range of clinical presentations. With the advances in computed tomography (CT) technology and easier access to CT, the incidence of incidentally diagnosed cases of PTE has increased. The main aim of our study was to determine the frequency of patients incidentally diagnosed with PTE and whether these patients differ from patients with symptomatic PTE in terms of case characteristics.

Materials and methods: We retrospectively analysed the charts of 148 patients with PTE diagnosed and treated in 2022. Demographic characteristics, thrombus localisation, risk factors, and treatment modalities were compared between symptomatic patients with clinically suspected PTE and patients with incidentally diagnosed PTE by imaging methods performed for other purposes without clinically suspected PTE.

Result: Out of 148 patients with PTE, 42 (28.3%) were diagnosed incidentally. The rate of concomitant malignancy was significantly higher in patients with incidental PTE (54.8%) than in patients with symptomatic PTE (28.3%) (p < 0.01). There was no significant difference between symptomatic and incidental PTE patients in terms of the pulmonary artery segment in which the thrombus was located (p > 0.05).

Conclusions: In our patient group, approximately one out of four patients diagnosed with PTE were incidentally diagnosed. Patients with malignancies may not have symptoms suspicious for PTE or their symptoms may go unrecognized.

导言:肺血栓栓塞症(PTE)的临床表现多种多样。随着计算机断层扫描(CT)技术的进步和更容易获得 CT,偶然诊断出 PTE 病例的发生率有所增加。我们研究的主要目的是确定偶然诊断出 PTE 患者的频率,以及这些患者与有症状的 PTE 患者在病例特征方面是否存在差异:我们回顾性分析了 2022 年诊断和治疗的 148 例 PTE 患者的病历。比较了临床疑似 PTE 的无症状患者和因其他目的进行影像学检查而偶然诊断出 PTE 的患者的人口统计学特征、血栓定位、风险因素和治疗方式:结果:在 148 例 PTE 患者中,42 例(28.3%)是偶然诊断出的。偶发 PTE 患者合并恶性肿瘤的比例(54.8%)明显高于无症状 PTE 患者(28.3%)(P < 0.01)。就血栓所在的肺动脉段而言,无症状和偶发性PTE患者之间没有明显差异(P > 0.05):结论:在我们的患者群体中,大约每四名确诊为PTE的患者中就有一名是偶然确诊的。恶性肿瘤患者可能没有疑似 PTE 的症状,或者其症状可能未被察觉。
{"title":"Characteristics of patients with symptomatic and incidental pulmonary thromboembolism.","authors":"Başak Gönen, Pervin Hanci, Osman Nuri Hatipoğlu","doi":"10.5578/tt.202403946","DOIUrl":"https://doi.org/10.5578/tt.202403946","url":null,"abstract":"<p><strong>Introduction: </strong>Pulmonary thromboembolism (PTE) has a wide range of clinical presentations. With the advances in computed tomography (CT) technology and easier access to CT, the incidence of incidentally diagnosed cases of PTE has increased. The main aim of our study was to determine the frequency of patients incidentally diagnosed with PTE and whether these patients differ from patients with symptomatic PTE in terms of case characteristics.</p><p><strong>Materials and methods: </strong>We retrospectively analysed the charts of 148 patients with PTE diagnosed and treated in 2022. Demographic characteristics, thrombus localisation, risk factors, and treatment modalities were compared between symptomatic patients with clinically suspected PTE and patients with incidentally diagnosed PTE by imaging methods performed for other purposes without clinically suspected PTE.</p><p><strong>Result: </strong>Out of 148 patients with PTE, 42 (28.3%) were diagnosed incidentally. The rate of concomitant malignancy was significantly higher in patients with incidental PTE (54.8%) than in patients with symptomatic PTE (28.3%) (p < 0.01). There was no significant difference between symptomatic and incidental PTE patients in terms of the pulmonary artery segment in which the thrombus was located (p > 0.05).</p><p><strong>Conclusions: </strong>In our patient group, approximately one out of four patients diagnosed with PTE were incidentally diagnosed. Patients with malignancies may not have symptoms suspicious for PTE or their symptoms may go unrecognized.</p>","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"179-184"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of melanoma with atypical presentation. 一例表现不典型的黑色素瘤。
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403963
Çağla Tezduyan, Merih Yalçiner, Elif Berna Köksoy

Malignant melanoma, a cancer type with a high mortality rate and increasing incidence worldwide, primarily affects the skin but can also occur in various other organs and tissues, including the respiratory tract. Although primary lung malignant melanomas are rare, they are often diagnosed at advanced stages due to their asymptomatic nature, and their atypical presentations may lead to misdiagnosis as other malignancies. In this case report, a mass lesion almost completely filling the right lung initially led to the consideration of small cell lung carcinoma, but a definitive pathological diagnosis could not be obtained in subsequent studies. The diagnosis was confirmed by soft tissue biopsy taken from the anterior thoracic wall. Considering clinical, pathological, and radiological evaluations, possible diagnoses included sarcoma, small-cell lung cancer, and melanoma. The patient, diagnosed through multiple tissue sampling and detailed dermatological examination, presents an interesting atypical case. This case highlights that rare variants of melanoma can be mistaken for other cancer types, such as lung cancer, sarcoma, or lymphoma. Patients may not always present with a noticeable skin lesion; therefore, a meticulous skin examination is crucial in such cases. Malignant melanoma is a noteworthy disease, considering its increasing incidence and early diagnosis holds vital importance for appropriate treatment and management.

恶性黑色素瘤是一种死亡率很高的癌症类型,在全世界的发病率不断上升,它主要影响皮肤,但也可发生在其他各种器官和组织,包括呼吸道。虽然原发性肺恶性黑色素瘤非常罕见,但由于其无症状的特性,往往在晚期才被诊断出来,而且其不典型的表现可能导致误诊为其他恶性肿瘤。在本病例报告中,肿块病变几乎完全充满右肺,起初考虑为小细胞肺癌,但在随后的研究中无法获得明确的病理诊断。通过胸前壁软组织活检确诊。考虑到临床、病理和放射学评估,可能的诊断包括肉瘤、小细胞肺癌和黑色素瘤。该患者是通过多次组织取样和详细的皮肤病检查确诊的,是一个有趣的非典型病例。该病例突出表明,罕见的黑色素瘤变种可能会被误诊为其他癌症类型,如肺癌、肉瘤或淋巴瘤。患者可能并不总是伴有明显的皮肤病变,因此,对此类病例进行细致的皮肤检查至关重要。恶性黑色素瘤是一种值得注意的疾病,因为它的发病率越来越高,早期诊断对适当的治疗和管理至关重要。
{"title":"A case of melanoma with atypical presentation.","authors":"Çağla Tezduyan, Merih Yalçiner, Elif Berna Köksoy","doi":"10.5578/tt.202403963","DOIUrl":"10.5578/tt.202403963","url":null,"abstract":"<p><p>Malignant melanoma, a cancer type with a high mortality rate and increasing incidence worldwide, primarily affects the skin but can also occur in various other organs and tissues, including the respiratory tract. Although primary lung malignant melanomas are rare, they are often diagnosed at advanced stages due to their asymptomatic nature, and their atypical presentations may lead to misdiagnosis as other malignancies. In this case report, a mass lesion almost completely filling the right lung initially led to the consideration of small cell lung carcinoma, but a definitive pathological diagnosis could not be obtained in subsequent studies. The diagnosis was confirmed by soft tissue biopsy taken from the anterior thoracic wall. Considering clinical, pathological, and radiological evaluations, possible diagnoses included sarcoma, small-cell lung cancer, and melanoma. The patient, diagnosed through multiple tissue sampling and detailed dermatological examination, presents an interesting atypical case. This case highlights that rare variants of melanoma can be mistaken for other cancer types, such as lung cancer, sarcoma, or lymphoma. Patients may not always present with a noticeable skin lesion; therefore, a meticulous skin examination is crucial in such cases. Malignant melanoma is a noteworthy disease, considering its increasing incidence and early diagnosis holds vital importance for appropriate treatment and management.</p>","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"229-232"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bispectral index monitoring: Optimizing anesthesia in rigid bronchoscopy. 双频谱指数监测:优化硬质支气管镜检查中的麻醉。
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403938
Özal Adiyeke, Onur Sarban, Ergün Mendeş, Hilal Akça, Engin İhsan Turan, Barış Demirkol, Mehmet Akif Özgül, Funda Gümüş Özcan

Introduction: This study investigates the application of bispectral index (BIS) monitoring in rigid bronchoscopy to enhance anesthetic delivery and patient outcomes, a topic that remains underexplored.

Materials and methods: A retrospective analysis of 155 patients undergoing elective rigid bronchoscopy under general anesthesia was conducted. Patients were divided into BIS-monitored and conventional anesthesia groups. Inclusion criteria were adults aged over 18 years with American Society of Anesthesiologists (ASA) physical status I-IV.

Result: No significant demographic differences were found between the groups. The BIS group showed significant reductions in propofol usage (231.40 ± 74.63 mg vs. 190.19 ± 91.83 mg, p= 0.003) and prednol dosage (94.27 ± 42.56 mg vs. 79.71 ± 18.97 mg, p= 0.020). Remifentanil administration approached statistical significance (56.99 ± 34.69 mcg vs. 45.36 ± 36.75 mcg, p= 0.055).

Conclusions: No significant demographic differences were found between the groups. The BIS group showed significant reductions in propofol usage (231.40 ± 74.63 mg vs. 190.19 ± 91.83 mg, p= 0.003) and prednol dosage (94.27 ± 42.56 mg vs. 79.71 ± 18.97 mg, p= 0.020). Remifentanil administration approached statistical significance (56.99 ± 34.69 mcg vs. 45.36 ± 36.75 mcg, p= 0.055).

导言:本研究探讨了双频谱指数(BIS)监测在硬质支气管镜检查中的应用,以提高麻醉效果和患者预后,而这一课题仍未得到充分探索:对 155 名在全身麻醉下接受择期硬质支气管镜检查的患者进行了回顾性分析。患者被分为 BIS 监测组和常规麻醉组。纳入标准为 18 岁以上、美国麻醉医师协会(ASA)身体状况 I-IV 级的成年人:结果:两组之间没有发现明显的人口统计学差异。BIS 组的异丙酚用量(231.40 ± 74.63 mg vs. 190.19 ± 91.83 mg,p= 0.003)和泼尼松用量(94.27 ± 42.56 mg vs. 79.71 ± 18.97 mg,p= 0.020)明显减少。瑞芬太尼用量接近统计学意义(56.99 ± 34.69 微克 vs 45.36 ± 36.75 微克,p= 0.055):结论:两组之间没有发现明显的人口统计学差异。BIS 组的异丙酚用量(231.40 ± 74.63 mg vs. 190.19 ± 91.83 mg,p= 0.003)和泼尼松用量(94.27 ± 42.56 mg vs. 79.71 ± 18.97 mg,p= 0.020)明显减少。瑞芬太尼用量接近统计学意义(56.99 ± 34.69 微克 vs 45.36 ± 36.75 微克,p= 0.055)。
{"title":"Bispectral index monitoring: Optimizing anesthesia in rigid bronchoscopy.","authors":"Özal Adiyeke, Onur Sarban, Ergün Mendeş, Hilal Akça, Engin İhsan Turan, Barış Demirkol, Mehmet Akif Özgül, Funda Gümüş Özcan","doi":"10.5578/tt.202403938","DOIUrl":"https://doi.org/10.5578/tt.202403938","url":null,"abstract":"<p><strong>Introduction: </strong>This study investigates the application of bispectral index (BIS) monitoring in rigid bronchoscopy to enhance anesthetic delivery and patient outcomes, a topic that remains underexplored.</p><p><strong>Materials and methods: </strong>A retrospective analysis of 155 patients undergoing elective rigid bronchoscopy under general anesthesia was conducted. Patients were divided into BIS-monitored and conventional anesthesia groups. Inclusion criteria were adults aged over 18 years with American Society of Anesthesiologists (ASA) physical status I-IV.</p><p><strong>Result: </strong>No significant demographic differences were found between the groups. The BIS group showed significant reductions in propofol usage (231.40 ± 74.63 mg vs. 190.19 ± 91.83 mg, p= 0.003) and prednol dosage (94.27 ± 42.56 mg vs. 79.71 ± 18.97 mg, p= 0.020). Remifentanil administration approached statistical significance (56.99 ± 34.69 mcg vs. 45.36 ± 36.75 mcg, p= 0.055).</p><p><strong>Conclusions: </strong>No significant demographic differences were found between the groups. The BIS group showed significant reductions in propofol usage (231.40 ± 74.63 mg vs. 190.19 ± 91.83 mg, p= 0.003) and prednol dosage (94.27 ± 42.56 mg vs. 79.71 ± 18.97 mg, p= 0.020). Remifentanil administration approached statistical significance (56.99 ± 34.69 mcg vs. 45.36 ± 36.75 mcg, p= 0.055).</p>","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"191-196"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The need for a new classification system in chronic obstructive pulmonary disease. 慢性阻塞性肺病需要新的分类系统。
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403961
Esra Ertan Yazar

The current classification fails to fully meet the needs of physicians and COPD patients in clinical practice. The future classification should aim to prevent the development of disease in high-risk groups, enable early diagnosis before irreversible damage occurs, identify subgroups, and provide pathophysiological insight to inspire drug development. It would be reasonable to thoroughly examine and assess the contributing factors such as an increase in the annual decline of (FEV1), bronchial hyperresponsiveness, variable obstruction, FEV1 % predicted, blood eosinophil count, preserved ratio impaired spirometry (PRISm), and the subgroups of group B as potential additions to the new classification.

目前的分类无法完全满足医生和慢性阻塞性肺病患者在临床实践中的需求。未来的分类应旨在预防高危人群的疾病发展,在不可逆转的损害发生之前实现早期诊断,识别亚组,并提供病理生理学见解以启发药物开发。作为新分类的潜在补充,全面检查和评估各种致病因素是合理的,如(FEV1)年下降率增加、支气管高反应性、可变阻塞、FEV1 预测百分比、血嗜酸性粒细胞计数、肺活量保留比值受损(PRISm)和 B 组亚群。
{"title":"The need for a new classification system in chronic obstructive pulmonary disease.","authors":"Esra Ertan Yazar","doi":"10.5578/tt.202403961","DOIUrl":"https://doi.org/10.5578/tt.202403961","url":null,"abstract":"<p><p>The current classification fails to fully meet the needs of physicians and COPD patients in clinical practice. The future classification should aim to prevent the development of disease in high-risk groups, enable early diagnosis before irreversible damage occurs, identify subgroups, and provide pathophysiological insight to inspire drug development. It would be reasonable to thoroughly examine and assess the contributing factors such as an increase in the annual decline of (FEV1), bronchial hyperresponsiveness, variable obstruction, FEV1 % predicted, blood eosinophil count, preserved ratio impaired spirometry (PRISm), and the subgroups of group B as potential additions to the new classification.</p>","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"233-236"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of mycobacterial microscopy and culture results from clinical samples: A five-year analysis. 评估临床样本中的分枝杆菌显微镜检查和培养结果:五年分析
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403955
Ahmet Balikçi, Mehmet Erbakan, Aylin Babalik

Introduction: Ehrlich-Ziehl-Neelsen (EZN) staining and culture methods are often used to diagnose tuberculosis. This study aimed to determine the acidfast bacteria (AFS) positivity rates in various clinical samples sent to our laboratory over five years and the growth and resistance rates in two different (solid and liquid) cultures and compare them with the data from Türkiye and the world.

Materials and methods: A total of 62.456 clinic samples were accepted in the microbiology laboratory between 2019 and 2024. The mycobacterial culture was performed by searching for acid-resistant bacilli microscopically and parallel inoculation media [solid Löwenstein-Jensen (L-J) and MGIT 960 liquid]. Those growing in the MGIT 960 system were identified using BD MGIT TBC Identification test kits that detect the MPT64 antigen. AFS and MPT64 antigenpositive samples were identified as Mycobacterium tuberculosis complex (MTBC) while AFS-positive samples and MPT64 antigen-negative results were classified as non-tuberculous mycobacteria (NTM). Drug susceptibility testing was performed with the BACTEC MGIT 960 SIRE kit. Susceptibility to NTM samples was not performed.

Result: Out of a total of 120.829 samples, 95.101 were lung samples and 25.728 were extrapulmonary samples. AFS positivity was detected in 2961 (2.4%) samples. MTBC grew in 6854 (5.6%) samples, and NTM grew in 1506 (1.24%) samples. Contamination was detected in 7171 (5.9%) media. Two thousand one hundred and sixty-nine susceptibility tests were performed. Considering antibiotic resistance rates, isoniazid resistance was detected in 154 (7%), rifampicin resistance in 140 (6.4%), ethambutol resistance in 18 (0.8%), and streptomycin resistance in 120 (0.5%) samples. All four-drug resistance was observed in 91 (4.1%) samples. AFP positivity and resistance rates for rifampicin have decreased significantly, while there have been no significant changes in NTM rates over the years.

Conclusions: When our data was determined, the sensitivity of microscopy was low. It is understood that mycobacterial culture and microscopy must be evaluated together to exclude tuberculosis infection. The high mycobacterial culture positivity rate, which is 5.6%, is due to the high number of follow-up patients and new referrals. It is seen that the change in sensitivity rates is due to the period of the COVID-19 epidemic, and it is similar to World Health Organization (WHO) data.

导言:艾氏-齐氏-奈尔森(EZN)染色法和培养法通常用于诊断结核病。本研究旨在确定五年来送往本实验室的各种临床样本中耐酸细菌(AFS)的阳性率以及两种不同(固体和液体)培养物的生长和耐药率,并将其与土耳其和全球的数据进行比较:2019年至2024年期间,微生物实验室共接收了62456份临床样本。霉菌培养是通过显微镜和平行接种培养基[固体 Löwenstein-Jensen (L-J) 和 MGIT 960 液体]寻找耐酸杆菌。使用检测 MPT64 抗原的 BD MGIT TBC 鉴定试剂盒对在 MGIT 960 系统中生长的细菌进行鉴定。AFS 和 MPT64 抗原阳性样本被鉴定为复合结核分枝杆菌(MTBC),而 AFS 阳性样本和 MPT64 抗原阴性结果被归类为非结核分枝杆菌(NTM)。药敏试验采用 BACTEC MGIT 960 SIRE 试剂盒进行。未对 NTM 样品进行药敏试验:在 120 829 份样本中,95 101 份为肺部样本,25 728 份为肺外样本。在 2961 份(2.4%)样本中检测到 AFS 阳性。在 6854 份(5.6%)样本中检测到 MTBC 生长,在 1506 份(1.24%)样本中检测到 NTM 生长。在 7171 个(5.9%)培养基中检测到污染。共进行了 2169 次药敏试验。从抗生素耐药率来看,154 个样本(7%)对异烟肼产生了耐药性,140 个样本(6.4%)对利福平产生了耐药性,18 个样本(0.8%)对乙胺丁醇产生了耐药性,120 个样本(0.5%)对链霉素产生了耐药性。91份样本(4.1%)对所有四种药物均产生耐药性。AFP阳性率和利福平耐药率显著下降,而NTM耐药率多年来没有明显变化:在确定我们的数据时,显微镜检查的灵敏度较低。据了解,要排除结核感染,必须同时进行分枝杆菌培养和显微镜检查。分枝杆菌培养阳性率较高,为 5.6%,这是因为随访患者和新转诊患者较多。可以看出,敏感率的变化是由于 COVID-19 流行时期造成的,与世界卫生组织(WHO)的数据相似。
{"title":"Evaluation of mycobacterial microscopy and culture results from clinical samples: A five-year analysis.","authors":"Ahmet Balikçi, Mehmet Erbakan, Aylin Babalik","doi":"10.5578/tt.202403955","DOIUrl":"https://doi.org/10.5578/tt.202403955","url":null,"abstract":"<p><strong>Introduction: </strong>Ehrlich-Ziehl-Neelsen (EZN) staining and culture methods are often used to diagnose tuberculosis. This study aimed to determine the acidfast bacteria (AFS) positivity rates in various clinical samples sent to our laboratory over five years and the growth and resistance rates in two different (solid and liquid) cultures and compare them with the data from Türkiye and the world.</p><p><strong>Materials and methods: </strong>A total of 62.456 clinic samples were accepted in the microbiology laboratory between 2019 and 2024. The mycobacterial culture was performed by searching for acid-resistant bacilli microscopically and parallel inoculation media [solid Löwenstein-Jensen (L-J) and MGIT 960 liquid]. Those growing in the MGIT 960 system were identified using BD MGIT TBC Identification test kits that detect the MPT64 antigen. AFS and MPT64 antigenpositive samples were identified as Mycobacterium tuberculosis complex (MTBC) while AFS-positive samples and MPT64 antigen-negative results were classified as non-tuberculous mycobacteria (NTM). Drug susceptibility testing was performed with the BACTEC MGIT 960 SIRE kit. Susceptibility to NTM samples was not performed.</p><p><strong>Result: </strong>Out of a total of 120.829 samples, 95.101 were lung samples and 25.728 were extrapulmonary samples. AFS positivity was detected in 2961 (2.4%) samples. MTBC grew in 6854 (5.6%) samples, and NTM grew in 1506 (1.24%) samples. Contamination was detected in 7171 (5.9%) media. Two thousand one hundred and sixty-nine susceptibility tests were performed. Considering antibiotic resistance rates, isoniazid resistance was detected in 154 (7%), rifampicin resistance in 140 (6.4%), ethambutol resistance in 18 (0.8%), and streptomycin resistance in 120 (0.5%) samples. All four-drug resistance was observed in 91 (4.1%) samples. AFP positivity and resistance rates for rifampicin have decreased significantly, while there have been no significant changes in NTM rates over the years.</p><p><strong>Conclusions: </strong>When our data was determined, the sensitivity of microscopy was low. It is understood that mycobacterial culture and microscopy must be evaluated together to exclude tuberculosis infection. The high mycobacterial culture positivity rate, which is 5.6%, is due to the high number of follow-up patients and new referrals. It is seen that the change in sensitivity rates is due to the period of the COVID-19 epidemic, and it is similar to World Health Organization (WHO) data.</p>","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"185-190"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of mean platelet volume (MPV), MPV/PLATELET (PLT) ratio, and lymphocyte/monocyte ratio (LMR) as poor prognostic factor in EGFR-mutant lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor. 平均血小板体积(MPV)、MPV/PLATELET(PLT)比值和淋巴细胞/单核细胞比值(LMR)与表皮生长因子受体酪氨酸激酶抑制剂治疗的表皮生长因子受体突变肺腺癌的不良预后因素有关。
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403838
Hasret Gizem Kurt, Berna Akinci Özyürek, Yurdanur Erdoğan, Nalan Akyürek
<p><strong>Introduction: </strong>Platelets (PLT) and host systemic inflammatory response (SIR) are known to be effective in the aggregation of cancer cells and the formation of metastasis. There are studies pointing out to the prognostic efficacy of lymphocyte-monocyte ratio (LMR) showing SIR activation and mean platelet volume (MPV) values indicating platelet activation in various cancer types. We predict that easy-to-access hemogram parameters such as MPV, MPV/PLT, and LMR can be guiding in the clinical follow-up period of patients with epidermal growth factor receptor (EGFR) positive mutation and who received EGFR, tyrosine kinase inhibitor (TKI) in the first-line treatment in predicting the progression of the disease, predicting the survival time of the patients, and evaluating the response to treatment.</p><p><strong>Materials and methods: </strong>The study is retrospective and included patients with stage III and stage IV pulmonary adenocarcinoma with positive EGFR mutations and for whom TKI was used in the first-line treatment between January 2011 and January 2021. MPV, MPV/PLT, and LMR values of the patients were calculated before treatment. Age, sex, comorbidity, smoking history, TNM stage, metastasis localizations, EGFR mutation types, TKI treatments used in first-line treatment, and MPV, MPV/PLT, and LMR values at the 1st month of treatment were recorded. With Kaplan-Meier, six-month, one-year, three-year, and five-year survival rates, average life expectancy, and 95% confidence intervals for these periods were calculated. Variables that may affect progression and overall survival (OS) were determined by performing univariate and multivariate Cox regression analysis.</p><p><strong>Result: </strong>One hundred and two patients were included in the study. The mean age of the patients was 64.30 ± 12.6 years. Eighty-four patients were in stage IV at the time of diagnosis. The expected mean progression-free survival (PFS) period of the cases was found to be 13.3 months. The mean life expectancy of the cases was found to be 35.1 months. Web-based Cutoff Finder algorithm written in the R program (http://molpath.charite.de/cutoff) was used to determine the ideal cut points for MPV, MPV/PLT, and LMR. The cut-off values were found to be 7.55 fL for MPV, 0.251 for MPV/PLT, and 2.615 for LMR, respectively. In univariate Cox regression analysis, LMR level lower than 2.615 increased the rate of progression 1.747 times (95% confidence interval: 1.129-2.705) and the death rate 2.056 times (95% confidence interval: 1.217-3.475) (p= 0.012, p= 0.007). The mean PFS LMR cut-off value was 10.3 months, and 15.3 months, and mean OS durations were 25.1 months and 40.8 months for the groups with low and high cut-off values respectively (p= 0.011, p= 0.006 log-rank test). According to the results of multivariate Cox regression analysis, MPV/PLT < 0.251, smoking, presence of pleural and adrenal metastases, and gefitinib treatment were independent factors in det
导言众所周知,血小板(PLT)和宿主全身炎症反应(SIR)对癌细胞的聚集和转移的形成非常有效。有研究指出,淋巴细胞-单核细胞比值(LMR)显示了 SIR 的激活,而血小板平均体积(MPV)值则显示了血小板在各种癌症类型中的激活情况,因此具有预后效果。我们预测,MPV、MPV/PLT 和 LMR 等易于获得的血象参数可在表皮生长因子受体(EGFR)突变阳性且接受 EGFR、酪氨酸激酶抑制剂(TKI)一线治疗的患者的临床随访期间,在预测疾病进展、预测患者生存时间和评估治疗反应方面发挥指导作用:该研究为回顾性研究,纳入了2011年1月至2021年1月期间一线治疗中使用TKI的表皮生长因子受体(EGFR)突变阳性的III期和IV期肺腺癌患者。治疗前计算了患者的 MPV、MPV/PLT 和 LMR 值。记录患者的年龄、性别、合并症、吸烟史、TNM 分期、转移部位、表皮生长因子受体突变类型、一线治疗中使用的 TKI 治疗方法以及治疗第一个月的 MPV、MPV/PLT 和 LMR 值。通过 Kaplan-Meier,计算出了六个月、一年、三年和五年的生存率、平均预期寿命以及这些时间段的 95% 置信区间。通过进行单变量和多变量考克斯回归分析,确定了可能影响病情进展和总生存期(OS)的变量:研究共纳入 112 名患者。患者的平均年龄为(64.30 ± 12.6)岁。84 名患者在确诊时处于 IV 期。病例的预期平均无进展生存期(PFS)为 13.3 个月。病例的平均预期寿命为 35.1 个月。使用R程序(http://molpath.charite.de/cutoff)编写的基于网络的Cutoff Finder算法确定了MPV、MPV/PLT和LMR的理想切点。结果发现,MPV、MPV/PLT 和 LMR 的截断值分别为 7.55 fL、0.251 和 2.615。在单变量 Cox 回归分析中,LMR 水平低于 2.615 会使进展率增加 1.747 倍(95% 置信区间:1.129-2.705),死亡率增加 2.056 倍(95% 置信区间:1.217-3.475)(P= 0.012,P= 0.007)。低截断值组和高截断值组的平均PFS LMR截断值分别为10.3个月和15.3个月,平均OS持续时间分别为25.1个月和40.8个月(p= 0.011,p= 0.006 log-rank检验)。多变量 Cox 回归分析结果显示,MPV/PLT < 0.251、吸烟、胸膜和肾上腺转移以及吉非替尼治疗是决定 PFS 的独立因素。在多变量Cox回归分析中,男性、血小板增加、MPV>7.55、吉非替尼治疗和吸烟是决定OS的独立因素:MPV、MPV/PLT和LMR是潜在的生物标志物,可用于接受EGFR-TKI治疗的肺部ADC患者的临床随访。
{"title":"Association of mean platelet volume (MPV), MPV/PLATELET (PLT) ratio, and lymphocyte/monocyte ratio (LMR) as poor prognostic factor in EGFR-mutant lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor.","authors":"Hasret Gizem Kurt, Berna Akinci Özyürek, Yurdanur Erdoğan, Nalan Akyürek","doi":"10.5578/tt.202403838","DOIUrl":"https://doi.org/10.5578/tt.202403838","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Platelets (PLT) and host systemic inflammatory response (SIR) are known to be effective in the aggregation of cancer cells and the formation of metastasis. There are studies pointing out to the prognostic efficacy of lymphocyte-monocyte ratio (LMR) showing SIR activation and mean platelet volume (MPV) values indicating platelet activation in various cancer types. We predict that easy-to-access hemogram parameters such as MPV, MPV/PLT, and LMR can be guiding in the clinical follow-up period of patients with epidermal growth factor receptor (EGFR) positive mutation and who received EGFR, tyrosine kinase inhibitor (TKI) in the first-line treatment in predicting the progression of the disease, predicting the survival time of the patients, and evaluating the response to treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;The study is retrospective and included patients with stage III and stage IV pulmonary adenocarcinoma with positive EGFR mutations and for whom TKI was used in the first-line treatment between January 2011 and January 2021. MPV, MPV/PLT, and LMR values of the patients were calculated before treatment. Age, sex, comorbidity, smoking history, TNM stage, metastasis localizations, EGFR mutation types, TKI treatments used in first-line treatment, and MPV, MPV/PLT, and LMR values at the 1st month of treatment were recorded. With Kaplan-Meier, six-month, one-year, three-year, and five-year survival rates, average life expectancy, and 95% confidence intervals for these periods were calculated. Variables that may affect progression and overall survival (OS) were determined by performing univariate and multivariate Cox regression analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Result: &lt;/strong&gt;One hundred and two patients were included in the study. The mean age of the patients was 64.30 ± 12.6 years. Eighty-four patients were in stage IV at the time of diagnosis. The expected mean progression-free survival (PFS) period of the cases was found to be 13.3 months. The mean life expectancy of the cases was found to be 35.1 months. Web-based Cutoff Finder algorithm written in the R program (http://molpath.charite.de/cutoff) was used to determine the ideal cut points for MPV, MPV/PLT, and LMR. The cut-off values were found to be 7.55 fL for MPV, 0.251 for MPV/PLT, and 2.615 for LMR, respectively. In univariate Cox regression analysis, LMR level lower than 2.615 increased the rate of progression 1.747 times (95% confidence interval: 1.129-2.705) and the death rate 2.056 times (95% confidence interval: 1.217-3.475) (p= 0.012, p= 0.007). The mean PFS LMR cut-off value was 10.3 months, and 15.3 months, and mean OS durations were 25.1 months and 40.8 months for the groups with low and high cut-off values respectively (p= 0.011, p= 0.006 log-rank test). According to the results of multivariate Cox regression analysis, MPV/PLT &lt; 0.251, smoking, presence of pleural and adrenal metastases, and gefitinib treatment were independent factors in det","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"197-207"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shared and unique transcriptomic signature genes and pathways among biopsy, peripheral blood mononuclear cells and bronchoalveolar lavage samples in IPF patients revealed using comparative meta-transcriptome analysis. 利用元转录组比较分析揭示 IPF 患者活检、外周血单核细胞和支气管肺泡灌洗样本中共享和独特的转录组特征基因和通路。
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403859
Seha Akduman, Nur Ekimci Gürcan, Nehir Kizililsoley, Altay Burak Dalan, Ömer Faruk Bayrak, Emrah Nikerel

Introduction: Idiopathic pulmonary fibrosis (IPF) affects the tissue surrounding the alveoli and occurs when the lung tissue becomes thick and stiff for unknown reasons. Clinical findings are fairly well settled, but the molecular mechanisms of IPF are still poorly known.

Materials and methods: To further our understanding, we collected publicly available transcriptome dataset from IPF cohorts, grouped them according to sampling method [bronchoalveolar lavage (BAL), biopsy, blood], and performed comparative meta-transcriptome study to (I) unravel key pathways (II), set out differences in discovered genes, pathways, and functional annotation with respect to the sampling method, and (III) find biomarkers for early diagnosis.

Result: The resulting lists are also compared with DisGeNet reported genes, earlier work, and Kyoto encyclopedia of genes and genomes (KEGG) pathways. Several pathways are shared among BAL and biopsy samples while blood samples point to alternative pathways, indicating the noise in information obtained from these samples.

Conclusions: Common to all sampling methods, interleukin-10 pathway and extracellular signaling pathways are pointed as further targets.

简介特发性肺纤维化(IPF)影响肺泡周围的组织,当肺部组织因不明原因变厚变硬时就会发生。临床发现已相当明确,但对 IPF 的分子机制仍知之甚少:为了加深理解,我们从 IPF 队列中收集了可公开获得的转录组数据集,根据取样方法(支气管肺泡灌洗(BAL)、活检、血液)对其进行分组,并进行了元转录组比较研究,以(I)揭示关键通路(II),列出发现的基因、通路和功能注释在取样方法上的差异,以及(III)寻找早期诊断的生物标志物:结果:所得出的清单还与 DisGeNet 报告的基因、早期工作以及京都基因和基因组百科全书(KEGG)途径进行了比较。BAL样本和活检样本共享了几条通路,而血液样本则指向了其他通路,这表明从这些样本中获得的信息存在噪声:结论:白细胞介素-10通路和细胞外信号通路是所有采样方法的共同目标。
{"title":"Shared and unique transcriptomic signature genes and pathways among biopsy, peripheral blood mononuclear cells and bronchoalveolar lavage samples in IPF patients revealed using comparative meta-transcriptome analysis.","authors":"Seha Akduman, Nur Ekimci Gürcan, Nehir Kizililsoley, Altay Burak Dalan, Ömer Faruk Bayrak, Emrah Nikerel","doi":"10.5578/tt.202403859","DOIUrl":"10.5578/tt.202403859","url":null,"abstract":"<p><strong>Introduction: </strong>Idiopathic pulmonary fibrosis (IPF) affects the tissue surrounding the alveoli and occurs when the lung tissue becomes thick and stiff for unknown reasons. Clinical findings are fairly well settled, but the molecular mechanisms of IPF are still poorly known.</p><p><strong>Materials and methods: </strong>To further our understanding, we collected publicly available transcriptome dataset from IPF cohorts, grouped them according to sampling method [bronchoalveolar lavage (BAL), biopsy, blood], and performed comparative meta-transcriptome study to (I) unravel key pathways (II), set out differences in discovered genes, pathways, and functional annotation with respect to the sampling method, and (III) find biomarkers for early diagnosis.</p><p><strong>Result: </strong>The resulting lists are also compared with DisGeNet reported genes, earlier work, and Kyoto encyclopedia of genes and genomes (KEGG) pathways. Several pathways are shared among BAL and biopsy samples while blood samples point to alternative pathways, indicating the noise in information obtained from these samples.</p><p><strong>Conclusions: </strong>Common to all sampling methods, interleukin-10 pathway and extracellular signaling pathways are pointed as further targets.</p>","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"208-218"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality? 吸入皮质类固醇是否能有效降低 COVID-19 肺炎的严重程度和死亡率?
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403934
Hatice Kiliç, Emine Argüder, Musa Civak, Emin Gemcioğlu, Ayşe Kaya Kalem, İmran Hasanoğlu, Bircan Kayaaslan, Sibel Günay, Esmehan Akpinar, Habibe Hezer, Ebru Şengül Şeref Parlak, Filiz Sadi Aykan, Yasin Kocaman, Esra Ünsay Metan, Mükremin Er, Aynil Dalkiran, Hülya Çelenk Ergüden, Zeynep Hancioğlu, Emre Altin, Eren Ceylan, Fatma Eser, Adalet Altunsoy Aypak, Esragül Akinci, Selma Karaahmetoğlu, Emra Asfuroğlu Kalkan, Osman Inan, Abdürrezzak Yilmaz, Bağdagül Yüksel Güler, Esra Çopuroğlu, Işıl Özkoçak Turan, Emre Demir, Serhat Hayme, Derya Gökmen, Aziz Ahmet Surel, Ebru Ünsal, Hatice Canan Hasanoğlu, İhsan Ateş, Rahmet Güner, Ayşegül Karalezli

Introduction: It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia.

Materials and methods: The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed.

Result: In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05).

Conclusions: In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.

导言:众所周知,使用吸入性皮质类固醇会增加慢性哮喘和慢性阻塞性肺病(COPD)随访患者的肺炎发病率。本研究旨在调查 COVID-19 肺炎病例中吸入类固醇对肺炎严重程度和死亡率的影响:本研究是一项回顾性观察研究。在大流行病诊所收治的病例中,诊断为 COVID-19 肺炎的患者被纳入其中。研究计划比较接受和未接受吸入皮质类固醇治疗的病例的肺炎严重程度和死亡率。为了确定死亡率的风险因素,我们进行了单变量和多变量负二项回归分析:我们在研究中发现,540 例(75%)病例未使用吸入性皮质类固醇(第 1 组),180 例(25%)病例使用了吸入性皮质类固醇(第 2 组)。比较了第一组和第二组病例的肺炎严重程度,两组之间无明显差异(P= 0.11)。然后,对影响所有病例死亡率的风险因素进行了单变量分析。结果发现,年龄增大、使用机械通气、重症肺炎、间质性肺病和俯卧位是影响死亡率的重要因素(P<0.05):总之,在我们的研究中发现,吸入皮质类固醇并不会增加肺炎的严重程度和死亡率。我们认为,当因哮喘和慢性阻塞性肺病而接受吸入皮质类固醇治疗的患者出现 COVID-19 肺炎时,他们所接受的治疗可以继续。
{"title":"Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?","authors":"Hatice Kiliç, Emine Argüder, Musa Civak, Emin Gemcioğlu, Ayşe Kaya Kalem, İmran Hasanoğlu, Bircan Kayaaslan, Sibel Günay, Esmehan Akpinar, Habibe Hezer, Ebru Şengül Şeref Parlak, Filiz Sadi Aykan, Yasin Kocaman, Esra Ünsay Metan, Mükremin Er, Aynil Dalkiran, Hülya Çelenk Ergüden, Zeynep Hancioğlu, Emre Altin, Eren Ceylan, Fatma Eser, Adalet Altunsoy Aypak, Esragül Akinci, Selma Karaahmetoğlu, Emra Asfuroğlu Kalkan, Osman Inan, Abdürrezzak Yilmaz, Bağdagül Yüksel Güler, Esra Çopuroğlu, Işıl Özkoçak Turan, Emre Demir, Serhat Hayme, Derya Gökmen, Aziz Ahmet Surel, Ebru Ünsal, Hatice Canan Hasanoğlu, İhsan Ateş, Rahmet Güner, Ayşegül Karalezli","doi":"10.5578/tt.202403934","DOIUrl":"10.5578/tt.202403934","url":null,"abstract":"<p><strong>Introduction: </strong>It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia.</p><p><strong>Materials and methods: </strong>The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed.</p><p><strong>Result: </strong>In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05).</p><p><strong>Conclusions: </strong>In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.</p>","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"219-228"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of thoracic aortic aneurysm with long-term hoarseness as the sole symptom. 一例以长期声音嘶哑为唯一症状的胸主动脉瘤患者。
Pub Date : 2024-09-01 DOI: 10.5578/tt.202403944
Mayu Kazui, Hiroaki Matsumoto, Yosuke Maezawa, Shinichiro Okauchi, Gen Ohara, Hiroaki Satoh
{"title":"A case of thoracic aortic aneurysm with long-term hoarseness as the sole symptom.","authors":"Mayu Kazui, Hiroaki Matsumoto, Yosuke Maezawa, Shinichiro Okauchi, Gen Ohara, Hiroaki Satoh","doi":"10.5578/tt.202403944","DOIUrl":"10.5578/tt.202403944","url":null,"abstract":"","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 3","pages":"237-238"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Co-existence of sarcoidosis and pulmonary embolism. 肉样瘤病与肺栓塞并存。
Pub Date : 2024-06-01 DOI: 10.5578/tt.202402917
Övgü Velioğlu Yakut, Miraç Öz, Serhat Erol, Öznur Yildiz, Özlem Özdemir Kumbasar
{"title":"Co-existence of sarcoidosis and pulmonary embolism.","authors":"Övgü Velioğlu Yakut, Miraç Öz, Serhat Erol, Öznur Yildiz, Özlem Özdemir Kumbasar","doi":"10.5578/tt.202402917","DOIUrl":"10.5578/tt.202402917","url":null,"abstract":"","PeriodicalId":519894,"journal":{"name":"Tuberkuloz ve toraks","volume":"72 2","pages":"173-175"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141312716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Tuberkuloz ve toraks
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1